← Leaderboards
Tiffany Tsang
University Of Pennsylvania
$67,336
Attributed
$67,336
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $45K · FY2019–20$50K$37.5K$25K$12.5K$0
'19
'20
Funding mix
By agency
NIH$67,336 · 1
By mechanism
F31$67,336 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Joshua L Dunaief$17,622,335
- Jerry D Glickson$20,468,757
- Michael S Marks$18,307,737
- Mariusz A Wasik$8,531,349
- Meenhard Herlyn$50,214,821
Others in their field
Other Emerging Leaders on “Affinity Chromatography”
- Sheng-Cheng Wu · Lectenz Bio, Inc.$4,528,775
- Ana Milosevic · Rockefeller University$4,341,388
- Danielle L Swaney · University Of California, San Francisco$3,683,633
- Giffin Daughtridge · Ursure, Inc.$3,350,060
- Silvia De Rubeis · Icahn School Of Medicine At Mount Sinai$3,271,893
- Nobuyuki Ishibashi · Children'S Research Institute$3,246,182
Research focus
Affinity ChromatographyAmino AcidsAntineoplastic AgentsBaseBindingBinding SitesBiochemical ReactionBraf GeneCell GrowthCell LineCell NucleusChelating AgentsChelationChelation TherapyCofactorCohortCombined Modality TherapyCopperCrispr/Cas TechnologyCytostaticsDrug ResistanceEffectivenessEmbryoAblation
Grant awards (2)
Investigating paradoxical YAP activation as an emergent limitation to Cu chelation therapy in BRAF V600E-driven melanoma$22,320
F31 · FY2020 · CA · contact PI
Investigating paradoxical YAP activation as an emergent limitation to Cu chelation therapy in BRAF V600E-driven melanoma$45,016
F31 · FY2019 · CA · contact PI